Devin Razavi-Shearer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Devin Razavi-Shearer has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Homie Razavi
Center for Disease Analysis Foundation Lafayette Colorado USA
6 shared publications - Ivane Gamkrelidze
Center for Disease Analysis Foundation Lafayette Colorado USA
6 shared publications Homie Razavi
CDA Foundation Lafayette Colorado USA
5 shared publications- Sarah Blach
Center for Disease Analysis Foundation, Lafayette, CO, USA
4 shared publications - Ellen Mooneyhan
Center for Disease Analysis Foundation (CDAF) Lafayette Colorado USA
3 shared publications - Carolyn Wallace
Center for Disease Analysis Foundation Lafayette Colorado USA
2 shared publications
Latest Publications
- Open Access
- 17 August 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (9) , e70222
Risk of Liver Cancer From Major Causes Compared to Smoking and Lung Cancer: A Systematic Review and Meta‐Analysis
Liver cancer is the second leading cause of premature cancer mortality globally, whose main causes—HBV, HCV, MASH and alcohol use—are preventable. Viral hepatitis' carcinogenicity is not as well‐known as the risk of lung cancer from smoking, leading to rising rates of liver cancer worldwide. The aim of this study was to compare the risk of liver cancer in HBV, HCV, HDV, MASH and alcohol consumption with the better‐known risk of lung cancer associated with smoking. We extracted the relative risk of liver cancer from HBV, HCV, HDV, MASH, and alcohol use and the relative risk of lung cancer from smoking from previous studies. We included cohort, case–control and nested case–control studies published as original articles. Odds ratios for each factor were pooled globally and by region to test for significant differences. One hundred and twenty‐six studies with 86,097,714 participants were included. Relative to the risk of lung cancer and currently smoking (OR 6.0), HBV (OR 15.2, p < 0.001), HCV (OR 12.8, p < 0.01) and HDV (OR 23.5, p < 0.01) were significantly associated with a higher risk of liver cancer, while MASLD (OR 2.6, p < 0.01) and alcohol use (OR 2.4, p < 0.001) were significantly associated with a lower risk of liver cancer. There was no statistically significant difference in liver cancer risk across regions. These findings highlight that viral hepatitis is a carcinogenic infectious disease. Better integration of HCC surveillance within the management of viral hepatitis is critical.
- 17 August 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (9) , e70222
Open AccessRisk of Liver Cancer From Major Causes Compared to Smoking and Lung Cancer: A Systematic Review and Meta‐Analysis
Liver cancer is the second leading cause of premature cancer mortality globally, whose main causes—HBV, HCV, MASH and alcohol use—are preventable. Viral hepatitis' carcinogenicity is not as well‐known as the risk of lung cancer from smoking, leading to rising rates of liver cancer worldwide. The aim of this study was to compare the risk of liver cancer in HBV, HCV, HDV, MASH and alcohol consumption with the better‐known risk of lung cancer associated with smoking. We extracted the relative risk of liver cancer from HBV, HCV, HDV, MASH, and alcohol use and the relative risk of lung cancer from smoking from previous studies. We included cohort, case–control and nested case–control studies published as original articles. Odds ratios for each factor were pooled globally and by region to test for significant differences. One hundred and twenty‐six studies with 86,097,714 participants were included. Relative to the risk of lung cancer and currently smoking (OR 6.0), HBV (OR 15.2, p < 0.001), HCV (OR 12.8, p < 0.01) and HDV (OR 23.5, p < 0.01) were significantly associated with a higher risk of liver cancer, while MASLD (OR 2.6, p < 0.01) and alcohol use (OR 2.4, p < 0.001) were significantly associated with a lower risk of liver cancer. There was no statistically significant difference in liver cancer risk across regions. These findings highlight that viral hepatitis is a carcinogenic infectious disease. Better integration of HCC surveillance within the management of viral hepatitis is critical.
- Open Access
- 25 May 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 65, 101712
From targets to real world impact: a review of models of care for chronic HBV and HCV in Europe
- 25 May 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 65, 101712
Open AccessFrom targets to real world impact: a review of models of care for chronic HBV and HCV in Europe
- Open Access
- 19 December 2025
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (1) , e70122
The Current Burden of Hepatitis B in the United States: A State, Territorial, and County Modelling Analysis
Accurate estimates of the prevalence of chronic hepatitis B virus (HBV) in the United States (US) are necessary for policy makers and community‐based organisations to make informed decisions regarding the allocation of resources to work towards the elimination of HBV as a public health threat. The primary aim of this study was to quantify the current HBV prevalence in the US at the state, county, and territorial level. The secondary aim was to quantify which countries of birth lead HBV infections. Using previously validated and published population‐based country level Markov models, the prevalence of HBV among immigrants in the US by country of birth was estimated in 2021. These estimates were then applied to county level population estimates from the 2018–2022 American Community Survey. This resulted in new county, state, territorial (Puerto Rico and Washington, D.C.), and national level HBV prevalence estimates. The total number of HBV infections in the US was estimated to be 1.7 million (UI: 795,000–4.1 million) corresponding to a prevalence of 0.50% (UI: 0.24%–1.23%). The state with the highest prevalence was Hawai‘i, 1.3% (UI: 0.5%–40%), while Wyoming was estimated to have the lowest prevalence, 0.2% (UI: 0.1%–1.1%). The largest number of total infections was found in California, 347,100 (UI: 193,700–729,200). The Aleutians West Census Area was the county with the highest prevalence, 2.9% (UI: 0.8%–9.7%), while Los Angeles County had the highest number of infections, 96,700 (UI: 54,800–190,600). These data can aid planners at all levels to better understand the complexities of HBV in the US. Thus, providing evidence for targeted public health interventions that will reduce the burden of HBV and improve the lives of those living with the disease.
- 19 December 2025
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (1) , e70122
Open AccessThe Current Burden of Hepatitis B in the United States: A State, Territorial, and County Modelling Analysis
Accurate estimates of the prevalence of chronic hepatitis B virus (HBV) in the United States (US) are necessary for policy makers and community‐based organisations to make informed decisions regarding the allocation of resources to work towards the elimination of HBV as a public health threat. The primary aim of this study was to quantify the current HBV prevalence in the US at the state, county, and territorial level. The secondary aim was to quantify which countries of birth lead HBV infections. Using previously validated and published population‐based country level Markov models, the prevalence of HBV among immigrants in the US by country of birth was estimated in 2021. These estimates were then applied to county level population estimates from the 2018–2022 American Community Survey. This resulted in new county, state, territorial (Puerto Rico and Washington, D.C.), and national level HBV prevalence estimates. The total number of HBV infections in the US was estimated to be 1.7 million (UI: 795,000–4.1 million) corresponding to a prevalence of 0.50% (UI: 0.24%–1.23%). The state with the highest prevalence was Hawai‘i, 1.3% (UI: 0.5%–40%), while Wyoming was estimated to have the lowest prevalence, 0.2% (UI: 0.1%–1.1%). The largest number of total infections was found in California, 347,100 (UI: 193,700–729,200). The Aleutians West Census Area was the county with the highest prevalence, 2.9% (UI: 0.8%–9.7%), while Los Angeles County had the highest number of infections, 96,700 (UI: 54,800–190,600). These data can aid planners at all levels to better understand the complexities of HBV in the US. Thus, providing evidence for targeted public health interventions that will reduce the burden of HBV and improve the lives of those living with the disease.
- 1 December 2025
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (1) , e70110
Modelling Micro‐Elimination: Third‐Trimester Tenofovir Prophylaxis for Perinatal Transmission of Hepatitis B in the Remote Dolpa District of Nepal
Hepatitis B (HBV) prevalence is very high in pregnant women in the Dolpa district of Nepal, a region characterised by a remote geographic landscape and low vaccination coverage. Using mathematical modelling, we evaluated the impact of third‐trimester tenofovir disoproxil fumarate (TDF) prophylaxis on HBV burden and estimated the time required to achieve HBV elimination in Dolpa. We developed a mathematical model to assess the impact of TDF prophylaxis on HBV elimination under four scenarios: baseline 50% vaccination coverage (scenario I ), 50% TDF and baseline vaccination coverage (scenario II ), 90% TDF plus baseline vaccination (scenario III ) and 90% TDF and birth‐dose plus 95% vaccination coverage (scenario IV ). We estimated the impact TDF prophylaxis has on HBV‐related morbidity and mortality and projected the time required for HBV elimination in the district. Our model suggests that HBV elimination is unlikely in Dolpa by 2100 under baseline interventions. The scale‐up of TDF coverage to 90% with the baseline vaccination significantly reduces HBV prevalence and HBV‐related mortality, making elimination possible in < 60 years. Implementing 90% TDF alongside birth‐dose vaccination and 95% infant HBV vaccination coverage could accelerate HBV elimination—≤ 0.1% HBV prevalence in children younger than 5 years–achieving it by 2045. In geographically inaccessible settings, a micro‐elimination approach using third‐trimester TDF is an effective and equitable strategy for HBV control. This approach is likely to substantially reduce HBV burden and HBV‐related mortality even before achieving elimination, while also addressing some of the challenges of immunoprophylaxis.
- 1 December 2025
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (1) , e70110
Modelling Micro‐Elimination: Third‐Trimester Tenofovir Prophylaxis for Perinatal Transmission of Hepatitis B in the Remote Dolpa District of Nepal
Hepatitis B (HBV) prevalence is very high in pregnant women in the Dolpa district of Nepal, a region characterised by a remote geographic landscape and low vaccination coverage. Using mathematical modelling, we evaluated the impact of third‐trimester tenofovir disoproxil fumarate (TDF) prophylaxis on HBV burden and estimated the time required to achieve HBV elimination in Dolpa. We developed a mathematical model to assess the impact of TDF prophylaxis on HBV elimination under four scenarios: baseline 50% vaccination coverage (scenario I ), 50% TDF and baseline vaccination coverage (scenario II ), 90% TDF plus baseline vaccination (scenario III ) and 90% TDF and birth‐dose plus 95% vaccination coverage (scenario IV ). We estimated the impact TDF prophylaxis has on HBV‐related morbidity and mortality and projected the time required for HBV elimination in the district. Our model suggests that HBV elimination is unlikely in Dolpa by 2100 under baseline interventions. The scale‐up of TDF coverage to 90% with the baseline vaccination significantly reduces HBV prevalence and HBV‐related mortality, making elimination possible in < 60 years. Implementing 90% TDF alongside birth‐dose vaccination and 95% infant HBV vaccination coverage could accelerate HBV elimination—≤ 0.1% HBV prevalence in children younger than 5 years–achieving it by 2045. In geographically inaccessible settings, a micro‐elimination approach using third‐trimester TDF is an effective and equitable strategy for HBV control. This approach is likely to substantially reduce HBV burden and HBV‐related mortality even before achieving elimination, while also addressing some of the challenges of immunoprophylaxis.
- Open Access
- 2 September 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 58, 101452
Estimating the impact of displacement from Ukraine on HBV and HCV prevalence among migrants in the European Union, 2024: a modeling study
- 2 September 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 58, 101452
Open AccessEstimating the impact of displacement from Ukraine on HBV and HCV prevalence among migrants in the European Union, 2024: a modeling study
- Open Access
- 8 May 2024
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 31 (S2) , 23-26
The economic argument for hepatitis B treatment simplification and expansion
One component of decisions regarding hepatitis B virus (HBV) treatment simplification and expansion is the economic perspective. Literature was reviewed for studies which provide estimates for the economic impact of simplifying and expanding treatment eligibility. Eight published studies and four unpublished studies were included and all but one subset of one study found that expanding treatment criteria would result in programs that would be at minimum cost‐effective and most often highly cost‐effective.
- 8 May 2024
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 31 (S2) , 23-26
Open AccessThe economic argument for hepatitis B treatment simplification and expansion
One component of decisions regarding hepatitis B virus (HBV) treatment simplification and expansion is the economic perspective. Literature was reviewed for studies which provide estimates for the economic impact of simplifying and expanding treatment eligibility. Eight published studies and four unpublished studies were included and all but one subset of one study found that expanding treatment criteria would result in programs that would be at minimum cost‐effective and most often highly cost‐effective.
- 1 January 2024
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 23 (1) , e0162
Global HBV disease burden and current care gaps
- 1 January 2024
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 23 (1) , e0162
Global HBV disease burden and current care gaps
- Open Access
- 27 May 2023
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 22, 100516
The impact of immigration on hepatitis B burden in the United States: a modelling study
- 27 May 2023
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 22, 100516
Open AccessThe impact of immigration on hepatitis B burden in the United States: a modelling study
- 25 May 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 56 (3) , 519-528
Impact of expanding hepatitis B treatment guidelines: A modelling and economic impact analysis
Summary: Background: Antiviral treatment in patients with chronic hepatitis B (CHB) may decrease the risk of hepatocellular carcinoma (HCC) and death. However, only 2.2% of CHB patients receive antiviral treatment globally. The complexity and strictness of the current clinical practice guidelines may limit expanding the treatment coverage for CHB.Aims: To examine the impact of expanding treatment criteria on future disease burden in Korea, a hepatitis B virus (HBV) endemic country with high diagnostic rates.Materials: Dynamic country‐level data were used to estimate the HCC incidence, overall mortality and economic impact of three incremental scenarios compared to the base case in Korea through 2035.Results: In 2020, 1,409,000 CHB cases were estimated, with the majority born before 1995. All scenarios assumed treating 70% of eligible individuals. The first scenario removed viral load restrictions in cirrhotic patients, which would avert 13,000 cases of HCC and save 11,800 lives. The second scenario, lowering the alanine aminotransferase (ALT) level restriction to the upper limit of the normal in non‐cirrhotic patients, would avert 26,700 cases of HCC and save 23,300 lives. The last scenario removed the restriction by ALT and HBeAg in treating non‐cirrhotic individuals with a viral load of ≥2000 IU/ml, which would avert 43,300 cases of HCC and save 37,000 lives. All scenarios were highly cost‐effective.Conclusions: Simplifying and expanding treatment eligibility for CHB would save many lives and be highly cost‐effective when combined with high diagnostic rates. These dynamic country‐level data may provide new insights for their global application.
- 25 May 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 56 (3) , 519-528
Impact of expanding hepatitis B treatment guidelines: A modelling and economic impact analysis
Summary: Background: Antiviral treatment in patients with chronic hepatitis B (CHB) may decrease the risk of hepatocellular carcinoma (HCC) and death. However, only 2.2% of CHB patients receive antiviral treatment globally. The complexity and strictness of the current clinical practice guidelines may limit expanding the treatment coverage for CHB.Aims: To examine the impact of expanding treatment criteria on future disease burden in Korea, a hepatitis B virus (HBV) endemic country with high diagnostic rates.Materials: Dynamic country‐level data were used to estimate the HCC incidence, overall mortality and economic impact of three incremental scenarios compared to the base case in Korea through 2035.Results: In 2020, 1,409,000 CHB cases were estimated, with the majority born before 1995. All scenarios assumed treating 70% of eligible individuals. The first scenario removed viral load restrictions in cirrhotic patients, which would avert 13,000 cases of HCC and save 11,800 lives. The second scenario, lowering the alanine aminotransferase (ALT) level restriction to the upper limit of the normal in non‐cirrhotic patients, would avert 26,700 cases of HCC and save 23,300 lives. The last scenario removed the restriction by ALT and HBeAg in treating non‐cirrhotic individuals with a viral load of ≥2000 IU/ml, which would avert 43,300 cases of HCC and save 37,000 lives. All scenarios were highly cost‐effective.Conclusions: Simplifying and expanding treatment eligibility for CHB would save many lives and be highly cost‐effective when combined with high diagnostic rates. These dynamic country‐level data may provide new insights for their global application.
- 11 December 2021
- Published by Wiley in Liver International
- Vol. 42 (9) , 1930-1934
Progress towards achieving viral hepatitis B and C elimination in the Asia and Pacific region: Results from modelling and global reporting
In 2016, Asia and Pacific countries endorsed action plans for reaching viral hepatitis elimination targets set in the Global Health Sector Strategy (GHSS) for Viral Hepatitis 2016‐2021. We examine the region's progress by modelling disease burden and constructing the cascade of care. Between 2015 and 2020, chronic HBV prevalence declined from 4.69% to 4.30%, and HCV prevalence declined from 0.64% to 0.58%. The region achieved the 2020 target of 30% incidence reduction for HBV, whereas HCV incidence declined by 6%. Hepatocellular carcinoma incidence for HBV and HCV increased by 9% and 7%, respectively. Liver‐related deaths from HBV rose by 8%, and mortality attributable to HCV plateaued. Large testing and treatment gaps remained in 2019: only 13% of chronic HBV infections were diagnosed and 25% treated; 21% of chronic HCV infection were diagnosed and 11% treated. Viral hepatitis must become national priority with adequate funding to reach elimination goals by 2030.
- 11 December 2021
- Published by Wiley in Liver International
- Vol. 42 (9) , 1930-1934
Progress towards achieving viral hepatitis B and C elimination in the Asia and Pacific region: Results from modelling and global reporting
In 2016, Asia and Pacific countries endorsed action plans for reaching viral hepatitis elimination targets set in the Global Health Sector Strategy (GHSS) for Viral Hepatitis 2016‐2021. We examine the region's progress by modelling disease burden and constructing the cascade of care. Between 2015 and 2020, chronic HBV prevalence declined from 4.69% to 4.30%, and HCV prevalence declined from 0.64% to 0.58%. The region achieved the 2020 target of 30% incidence reduction for HBV, whereas HCV incidence declined by 6%. Hepatocellular carcinoma incidence for HBV and HCV increased by 9% and 7%, respectively. Liver‐related deaths from HBV rose by 8%, and mortality attributable to HCV plateaued. Large testing and treatment gaps remained in 2019: only 13% of chronic HBV infections were diagnosed and 25% treated; 21% of chronic HCV infection were diagnosed and 11% treated. Viral hepatitis must become national priority with adequate funding to reach elimination goals by 2030.